Merck & Co., Inc. (MRK)[Tv]

Key Developments

• Landmark Phase 3 success for Intismeran autogene, a personalized mRNA cancer vaccine developed with Moderna and combined with Keytruda, showing a 49% reduction in recurrence or death in high-risk melanoma patients—marking a transformative milestone in next-generation immuno-oncology and triggering a $43 billion market surge in a single day.
• FDA acceptance of the sBLA for ENFLONSIA, Merck’s pediatric RSV vaccine, with a March 22, 2027 PDUFA decision now serving as a high-stakes inflection point for the company’s diversification strategy and long-term growth narrative.
• Approval of Keytruda in combination with enfortumab vedotin for cisplatin-ineligible muscle-invasive bladder cancer in Canada—reinforcing Keytruda’s expanding label and market dominance with clinical data showing superior survival outcomes.
• Merck’s aggressive M&A strategy deepens with potential $2B acquisition of Revolution Medicines, aiming to secure daraxonrasib, a high-potential late-stage asset for pancreatic cancer—critical amid looming 2028 Keytruda patent expiry.
• $5.7 billion in one-time charges from the Terns Pharmaceuticals acquisition—driving a $1.3 billion GAAP loss in Q2 2026 and slashing full-year EPS guidance nearly in half—exposing the steep financial toll of Merck’s innovation-driven growth model.